Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Position Reduced by Atria Investments Inc

Atria Investments Inc trimmed its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 11.7% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 10,623 shares of the biopharmaceutical company’s stock after selling 1,405 shares during the quarter. Atria Investments Inc’s holdings in Amicus Therapeutics were worth $113,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in FOLD. American International Group Inc. boosted its holdings in shares of Amicus Therapeutics by 1.3% during the 1st quarter. American International Group Inc. now owns 143,034 shares of the biopharmaceutical company’s stock worth $1,685,000 after buying an additional 1,785 shares during the period. CANADA LIFE ASSURANCE Co grew its holdings in shares of Amicus Therapeutics by 7.8% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 100,538 shares of the biopharmaceutical company’s stock worth $1,183,000 after purchasing an additional 7,304 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Amicus Therapeutics by 0.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,389,361 shares of the biopharmaceutical company’s stock worth $16,368,000 after purchasing an additional 12,003 shares during the last quarter. Silvercrest Asset Management Group LLC grew its holdings in shares of Amicus Therapeutics by 4.5% in the 1st quarter. Silvercrest Asset Management Group LLC now owns 374,958 shares of the biopharmaceutical company’s stock worth $4,417,000 after purchasing an additional 16,033 shares during the last quarter. Finally, Bayesian Capital Management LP bought a new stake in shares of Amicus Therapeutics in the 1st quarter worth about $591,000.

Wall Street Analyst Weigh In

FOLD has been the topic of several analyst reports. Guggenheim upped their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Bank of America upped their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, October 17th. Cantor Fitzgerald upped their target price on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Morgan Stanley decreased their price objective on shares of Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, November 12th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $17.63.

Amicus Therapeutics Stock Up 1.7 %

Shares of NASDAQ:FOLD opened at $9.66 on Monday. Amicus Therapeutics, Inc. has a 12 month low of $9.02 and a 12 month high of $14.57. The company’s 50-day moving average price is $10.82 and its two-hundred day moving average price is $10.58. The company has a quick ratio of 2.42, a current ratio of 3.15 and a debt-to-equity ratio of 2.18. The firm has a market cap of $2.89 billion, a P/E ratio of -28.41 and a beta of 0.68.

Insider Activity

In other news, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $10.60, for a total value of $79,500.00. Following the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $9,398,532.40. This trade represents a 0.84 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In the last quarter, insiders have sold 30,401 shares of company stock valued at $352,038. 2.20% of the stock is currently owned by insiders.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.